Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 5, 2025, reports on Syndax Pharmaceuticals, Inc. (SNDX). The filing primarily serves to announce financial results for the quarter and year ended March 31, 2025, via a press release incorporated by reference as Exhibit 99.1. Additionally, the company reported a change in its principal executive offices effective March 1, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not detailed in the body of this 8-K document.
Material Changes
- Headquarters Relocation: Effective March 1, 2025, the Company moved its headquarters from Waltham, MA, to 730 Third Avenue, Floor 9, New York, NY 10017.
- Contact Information: The Company's telephone number remains unchanged at (781) 419-1400.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within its text. Investors are directed to the press release (Exhibit 99.1) for details regarding the financial results for the period ended March 31, 2025. The filing includes standard disclaimers that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release) for actual financial performance data for Q1 and FY 2025.
- Confirm the operational impact of the headquarters move to New York, NY.
- Verify the continued use of the existing telephone number for investor relations.